Metabolomic adaptations and correlates of survival to immune checkpoint blockade
Haoxin Li(Broad Institute), Marios Giannakis(Broad Institute), Aly‐Khan A. Lalani(Juravinski Cancer Centre), Stuart L. Schreiber(Broad Institute), Eliezer M. Van Allen(Dana-Farber Cancer Institute), Kevin Bullock(Broad Institute), Sabina Signoretti(Brigham and Women's Hospital), Carino Gurjao(Broad Institute), Toni K. Choueiri(Harvard University), Levi A. Garraway(Broad Institute), Clary B. Clish(Broad Institute), William R. Sellers(Broad Institute), David A. Braun(Yale Cancer Center), Gordon J. Freeman(Dana-Farber Cancer Institute), Chelsea Jin(Bristol-Myers Squibb (United States)), Sachet A. Shukla(Broad Institute), F. Stephen Hodi(Harvard University), Megan Wind‐Rotolo(Bristol-Myers Squibb (United States)), Shuba Gopal(Broad Institute), Dominick Bossé(Dana-Farber Cancer Institute), Christine E. Horak(Bristol-Myers Squibb (United States)), David F. McDermott(Beth Israel Deaconess Medical Center)
Cited by 222
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Regulation of Ferroptotic Cancer Cell Death by GPX4
|Cell|2014|7.5k
The Immune Landscape of Cancer
|Immunity|2018|6.2k